KUALA LUMPUR, July 21 -- Napier, provider of advanced anti-financial crime compliance solutions, has announced its global footprint extension by opening a new office at Dubai International Financial Centre (DIFC), the global financial centre and leading FinTech hub in the MEASA region.
Strategically located between East and West, DIFC is recognised as the leading financial centre in the Middle East, Africa and South Asia (MEASA). Located in the recently inaugurated Innovation Hub, part of the Dubai Future District, Napier’s new UAE base puts the RegTech provider at the centre of the region’s largest collection of financial services companies. London-headquartered Napier already works on AI-led anti-financial crime solutions with many organisations across MEASA, including Saudi Arabian Monetary Agency, Central Bank of UAE and directly with DIFC. The new UAE base forms part of a wider global strategy that sees the RegTech now established in all key financial hubs across the world, working with firms on KYC, AML and trade compliance. In a statement, Napier Chief Operating Officer, Greg Watson, said: “DIFC is recognised internationally as a leading global centre for FinTech and building a presence here will enable us to better serve our clients operating both locally and in international markets. “Innovations in technologies to improve financial compliance are a key part of the huge ambition that we see across the UAE as it strengthens its position as a modern global financial hub, so it’s very important for us to be here.” DIFC Authority Chief Business Development Officer Salmaan Jaffery said: “The world’s leading financial and FinTech institutions are based at DIFC and we are delighted to welcome Napier into the fold.” Napier works with international customers and has a presence in North America, Australia and Dubai, while its foothold in APAC was also strengthened recently with key senior hires from the industry and the addition of new offices in Singapore and Kuala Lumpur. -- BERNAMA
0 Comments
A better cost-effective option is now available for dietary supplement, functional food, and beverage manufacturers.
Rancho Santa Margarita, Calif., July 21 (Bernama-GLOBE NEWSWIRE) -- Blue California joins with the innovative Massachusetts-based biotech company Conagen to announce the commercialization of high-purity, fermentation-derived nicotinamide mononucleotide (NMN). A nature-based metabolic component which has caught the attention of health-conscious consumers for supporting energy and longevity. The quest to age healthily and support longevity is surging among health-conscious consumers. “Consumers are reassessing their dietary regimen to make room for ingredients that can support an increased healthspan,” said Chief Science Officer at Blue California, Dr. Priscilla Samuel. NMN supplements are highly sought-after for healthy aging applications, including brain health, vitality, heart health, metabolic health, and even cosmetics. However, current NMN ingredients used in products on the market are mostly produced by chemical synthesis. While consumers are exploring dietary supplements for a holistic approach to health, they are also demanding clean labels from their supplements, and moving away from synthetic ingredients. Blue California’s fermentation-derived NMN opens new opportunities for producers to consider consumers' health more holistically while acquiring a closer-to-nature position. NMN serves as a precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme present in all living cells and critical for mitochondrial function. Increased intracellular levels of NAD+ boost energy production and improve cellular health, but levels decline dramatically with age. Replenishing NAD+ in the body with its precursor NMN has been proposed as a way to possibly combat age-related degeneration and increase healthy lifespan. “Our fermentation-derived offering is well-positioned to capitalize on the growing recognition of NMN as an important ingredient in the food and supplement spaces,” said Samuel. “NMN is a well-known molecule in the longevity research community, and emerging research also suggests potential applications for immune health as well as sports nutrition.” Harvard professor David Sinclair, a well-recognized leader in the field of aging research, is an advocate of NMN for improving the health of aging populations. “NMN is a logical extension to our line of “longevity ingredients” which includes ergothioneine and pyrroloquinoline quinone. All of these molecules are made by our own proprietary fermentation processes, enabling our customers to better serve consumers who might reject chemically-derived ingredients,” said VP of Innovation at Conagen, Dr. Casey Lippmeier. “Because of the way we make it, Conagen’s NMN is of the highest purity and quality. It is also very cost-effective and compatible with clean-label trends, all of which demonstrates our strength as a strategic partner with Blue California.” As innovation in dietary supplemental nutrition advances, so does the growth of global vitamin, mineral and supplement (VMS) launches. Mintel reported a growth of 67% of global VMS launches in Apr 2020 - Mar 2021, as compared to Apr 2016 - Mar 2017 --- where the United States leads the VMS market. ### About Blue California Blue California is a vertically integrated technology company providing innovative ingredient solutions to global partners. With more than 20 years of innovation success, our ingredients are used in commercial products and applications in the industries of nutrition, personal care, healthy aging and wellness, functional food and beverage, and beauty. www.bluecal-ingredients.com About Conagen Conagen is making the impossible possible. Our scientists and engineers use the latest synthetic biology tools to develop high-quality sustainable nature-based products through systems of manufacturing on a molecular level and fermentation basis. We focus on the bioproduction of high-value ingredients for food, nutrition, flavors and fragrances, pharmaceutical, and renewable materials industries. www.conagen.com Attachment · Blue California NMN Press release Ana Arakelian Blue California ingredients +1-949-635-1991 [email protected] Source: Blue California Ingredients --BERNAMA KUALA LUMPUR, July 21 (Bernama) -- Riskified Ltd (Riskified), a fraud management platform enabling frictionless eCommerce, has announced the launch of its initial public offering of 17,500,000 Class A ordinary shares.
The offering consists of 17,300,000 Class A ordinary shares offered by Riskified and 200,000 Class A ordinary shares to be sold by one of Riskified’s existing shareholders. According to a statement, Riskified will not receive any proceeds from the sale of the shares by the selling shareholder. The underwriters will have a 30-day option to buy an additional 2,625,000 Class A ordinary shares from Riskified at the initial public offering price, less underwriting discounts and commissions. The initial public offering price is currently expected to be between US$18.00 and US$20.00 per share. Riskified intends to list its Class A ordinary shares on the New York Stock Exchange under the ticker symbol ‘RSKD’. (US$1 = RM4.232) Goldman Sachs & Co LLC, J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC are acting as lead book-running managers for the proposed offering. Meanwhile, Barclays Capital Inc, KeyBanc Capital Markets Inc, Piper Sandler & Co, Truist Securities Inc and William Blair & Company, L.L.C. are joint book-running managers for the proposed offering. A registration statement on Form F-1 relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted prior to the time the registration statement becomes effective. -- BERNAMA KUALA LUMPUR, July 21 (Bernama) -- Three AmInvest fixed income funds have been selected at this year’s FSMOne Recommended Unit Trusts Awards 2021/22 (“Awards”)1 in recognition of consistent outperformance amongst peers within their respective categories.
AmIncome Plus was listed as the recommended unit trust fund under the Core Fixed Income-Malaysia (Short Duration) category for the eighth year, whereas AmDynamic# Bond topped the Fixed Income-Malaysia with Foreign Exposure category for the sixth year running.1 In addition, AmTactical Bond was singled out as the recommended unit trust fund under the Fixed Income-Asia category this year.1 AmInvest is the fund management brand under AmInvestment Bank. The Awards assist investors to shortlist consistently performing unit trust funds amongst their peers. FSMOne is an online investment platform that distributes unit trusts, stocks, exchange traded funds, insurance, bonds and managed portfolios. For the Awards, unit trust funds with at least three years of track record (as at end March 2021) were rigorously assessed amongst peers in the same category. The methodology for fund assessment was based on a combination of quantitative and qualitative factors. The quantitative factors taken into account were historical performance, risk and expense ratio. Meanwhile, additional qualitative factors such as fund house’s investment philosophy and consistency in its investment approach were also considered to determine the winners in each category. Ms. Goh Wee Peng, Chief Executive of AmInvest, said, “With our stringent credit processes and superior credit selection by our in-house proprietary credit research unit spanning over four decades, we offer investors the opportunity to optimise returns with lower risk assets, within acceptable risk boundaries. Throughout the years, we have received various awards for our expertise in managing fixed income investments, including Best Bond Fund Family Group Over Three Years for the second year at the Refinitiv Lipper Fund Awards Malaysia 2021.3 Last year, we adopted dynamic asset allocation investment strategies for our AmDynamic# Bond and AmTactical Bond funds which provided the flexibility to switch between aggressive and defensive stances to capitalise on market conditions.” AmIncome Plus is suitable for investors with a short to medium-term investment horizon who want to invest the cash portion of their investment portfolio for the potential to reap regular income and to preserve capital. For a one-year period (as at March 2021), the fund posted a total return (a measure of the fund’s performance comprising income distribution and capital gains) of around 3.2% and 12.0% over a three-year period.2 AmDynamic# Bond seeks to optimise risk-adjusted returns for investors including interest rate expectations, currency movements and diversification opportunities through its exposure to both local as well as foreign bonds. This medium to long-term bond fund employs an active management investment strategy that seeks to increase returns by capitalising on market views and timing decisions, as opposed to a buy-and-hold strategy. The fund achieved a one-year total return of 4.4% and 20.7% over three years up to end March 2021.2 AmTactical Bond aims to provide income and to a lesser extent capital appreciation by investing primarily in local and foreign bonds. It is also a medium to long-term bond fund that is actively managed in which its trading activities will depend on investment opportunities. Over one-year and three-year periods (as at March 2021), the fund has registered total return of 7.0% and 20.0% respectively.2 About AmInvest AmInvest is the brand name for the funds management business of AmFunds Management Berhad and AmIslamic Funds Management Sdn Bhd, both of which are wholly owned subsidiaries of AmInvestment Bank Berhad. We are a multiple award-winning fund manager based in Malaysia with 40 years of investing experience managing unit trust funds, wholesale funds, institutional mandates, Exchange Traded Funds (ETF) and Private Retirement Scheme (PRS); encompassing both conventional and Shariah-compliant funds. Sources and Notes: # The word “Dynamic” in the context refers to the fund’s investment strategy which is active management, not buy-and-hold strategy. 1 iFAST Capital Sdn Bhd, July 2021. 2 Based on performance data for AmIncome Plus, AmDynamic# Bond and AmTactical Bond B MYR compiled by Lipper, Refinitiv, as at 31 March 2021. Performance is shown in Malaysian Ringgit on a NAV price basis with income distribution reinvested. Performance figures are calculated net of all fees, charges and expenses, except entry charge and exit penalty (if any). Past performance is not indicative of future performance. 3 Refinitiv Lipper Fund Awards Malaysia 2021, March 2021. SOURCE : AmBank Group HONG KONG, July 19 (Bernama-BUSINESS WIRE) -- Regencell Bioscience Holdings Limited (NASDAQ:RGC) (“Regencell” or the “Company”), an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine (“TCM”) for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder (“ADHD”) and Autism Spectrum Disorder (“ASD”), today announced the pricing of its initial public offering (“Offering”) of 2,300,000 ordinary shares at a public offering price of $9.50 per ordinary share. The ordinary shares have been approved for listing on the Nasdaq Capital Market and are expected to commence trading on July 16, 2021 under the ticker symbol “RGC.”
Regencell expects to receive aggregate gross proceeds of approximately $21.9 million from this Offering, before deducting underwriting discounts and other related expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 345,000 ordinary shares at the public offering price, less underwriting discounts. The Offering is expected to close on or about July 20, 2021, subject to the satisfaction of customary closing conditions. mrem.bernama.com/viewsm.php?idm=40560 |
Archives
April 2023
|